Lansoprazol Medical Valley (Lansoprazole)

Lansoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway, providing therapeutic benefit in several acid‑related disorders.

• Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation.
• Peptic ulcer disease: accelerates ulcer healing and lowers the risk of recurrence.
• Prevention of NSAID‑induced gastric ulcers: decreases the likelihood of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs.

• Lansoprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly reduces gastric acidity, allowing damaged mucosa to heal and preventing further acid‑related injury.

Adverse reactions may occur with lansoprazole use.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Diarrhea: loose stools that usually resolve with continued therapy.
• Nausea: occasional feeling of queasiness after dosing.
• Abdominal pain: mild discomfort in the upper abdomen.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis, angioedema): require immediate medical attention.
• Clostridioides difficile infection: may present with severe diarrhea.
• Low magnesium levels (hypomagnesemia): can cause muscle cramps, seizures, or cardiac arrhythmias.

Before initiating therapy, consider the following safety measures.

• Assess renal function: adjust use in patients with severe renal impairment.
• Avoid in known hypersensitivity: discontinue if rash or other allergic signs develop.
• Monitor for drug interactions: especially with warfarin, clopidogrel, and certain antivirals.
• Use caution in pregnancy: limited data, benefits should outweigh potential risks.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir: decreased absorption, compromising antiviral efficacy.
• Methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring closer coagulation monitoring.
• Digoxin: possible rise in serum levels, necessitating dose adjustment.
• Phenytoin: reduced plasma concentrations, which may lessen seizure control.